warmer, thermoneutral temperature (TT). Housing mice at TT substantially reduces norepinephrine and β-AR signaling on immune cells (22). Treatment of allo-HCT mice housed at ST with the pan-beta blocker propranolol increased aGvHD severity, indicating that β-AR signaling is protective against aGvHD (22). Furthermore, we demonstrated that blockade of recipient β2-ARs enhanced the GvT effect by modulating antigen presenting cells (23). It was critical to continue to define the role of T cell β2-AR signaling, especially CD4 + T cell differentiation. In addition, the detailed mechanisms of β2-AR signaling and its downstream effects on immunomodulation after allo-HCT remained incompletely understood.Adrenergic receptors (ARs) are G protein-coupled receptors, classified into 2 general classes: α-ARs and β-ARs. The α1-AR is primarily expressed on endothelial cells, and the α2-AR is more ubiquitously expressed. β1-ARs and β3-ARs are primarily expressed in cardiac and adipose tissues, respectively, while β2-ARs are extensively distributed especially in the respiratory tract (24, 25) and on immune cells (26,27). Emerging studies reinforce an inhibitory role of β2-AR signaling on T cell function, especially CD8 + T cells, in preclinical and clinical tumor models (27,28). The β2-AR is activated by catecholamines (norepinephrine and epinephrine), released by the sympathetic nervous system (27, 29) and splenic tyrosine hydroxylase-expressing cells (30). This β2-AR-mediated regulation affects T cell antitumor functions (28), DC antigen presentation (23), B cell expression of costimulatory molecules (31, 32), and myeloid-derived suppressor cell (MDSC) immunosuppression ( 26).Thus, we focused on the role of β2-AR signaling on immune cell development and pathways during aGvHD. We asked whether β2-AR expression by allogeneic donor T cells modulates aGvHD pathology and how this modulation occurs. Using major histocompatibility complex (MHC) and minor histocompatibility antigen (miHA) mismatched HCT murine models, and a humanized NOD-scid IL-2Rγ -/-(NSG) model of aGvHD, we demonstrate that β2-AR expression by allogeneic T cells regulates the differentiation of CD4 + T cells from Th1/Th17 to a Th2/Treg phenotype, ameliorating aGvHD without compromising GvT. These data lead us to propose that selective β2-AR agonists may serve as potential therapeutic agents to attenuate aGvHD while preserving the GvT effect.